You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils

À propos des lignes directrices

The Role of High Dose Rate Brachytherapy in the Palliation of Symptom in Patients with Non-Small Cell Lung Cancer

Version: 4 ID: 7-16 déc 2022

Type of Content: Guidelines & Advice, Clinical

Document Status: Current

Authors:

Lung Cancer Disease Site Group

Patient Population

Adult patients with symptomatic endobronchial disease in non-small cell lung cancer.

Research Question(s)

Is there a role for high dose rate endobronchial brachytherapy (HDREB) in the palliation of respiratory symptoms in patients with non-small cell lung cancer?
If so, what is the optimal dose of HDREB in this setting?

Summary (PDF) (198.14 Ko)

Full Report (PDF) (1.36 Mo)